CLYMClimb Bio Inc

Sign up free
⚡

Climb Bio Reports Third Quarter 2026 Financial Results and Provides Business Updates - GlobeNewswire

GlobeNewswire · Nov 5, 12:00 PM

Market reactionShares rose 16% on Nov 6. Investing.com: “Oppenheimer reiterates Climb Bio stock rating on SLE data”

IntactLast material event Sep 3, 2026 · Updated Oct 26, 2026

PrisMN shows antibody reductions; higher-dose ITP and lupus results remain next

Climb Bio is a clinical-stage company developing two antibodies for immune-mediated diseases: budoprutug, which depletes B cells by targeting CD19, and CLYM116, which targets APRIL in IgA nephropathy; neither is approved.

Climb's case rests on anti-CD19 budoprutug and anti-APRIL CLYM116. Early ITP responses and PrisMN antibody reductions support development, but faster clearance in proteinuric patients makes dose selection important. Higher-dose ITP and global lupus data remain expected in Q4 2026; additional PrisMN data are anticipated in 2027. CLYM116's healthy-volunteer pharmacology supports extended dosing; NAVIGATE-2 must confirm the regimen in patients. Pivotal development depends on regulatory feedback. Management projects funding into the second half of 2028 under its current operating plan.

Thesis checklist

0 risks need attention

Select a row for evidence
Higher ITP doses deepen platelet responsesAwaiting evidenceNext: Additional 500 mg and 1000 mg ITP cohort results expected in Q4 2026.

Why it is in this state

The evidence, what would weaken it and the source filing

First membranous nephropathy and lupus data show B-cell and antibody effectsAwaiting evidenceNext: Global lupus safety and biomarker data expected in Q4 2026; additional PrisMN data anticipated in 2027.

Why it is in this state

The evidence, what would weaken it and the source filing

NAVIGATE-2 confirms every-12-week dosingAwaiting evidenceNext: Initial NAVIGATE-2 patient data expected in the first half of 2027.

Why it is in this state

The evidence, what would weaken it and the source filing

Cash lasts into the second half of 2028SupportedNext: Next reported cash balance and spending plans as later-stage development approaches.

Why it is in this state

The evidence, what would weaken it and the source filing

Next decision point

Can higher budoprutug doses deepen durable platelet responses?

Tests: Higher ITP doses deepen platelet responses

Q4 2026

Do higher doses improve the depth and durability of platelet responses without compromising tolerability?

Strong, inconclusive and weak outcomes

What to look for in the result and how each would move the checklist

Questions to investigate

History

Price and material events

Select an event marker to read the update below. Marker colors show Thesis status.

IntactCurrentClinical
+6.4%Sep 3, 2026

PrisMN shows antibody reductions; higher-dose ITP and lupus results remain next

About this history: every entry shows when the Thesis moved and what it said. The reasoning behind each move (the evidence, the analysis and the source filing) and the earnings write-ups are part of a subscription.

Pipeline

Immune thrombocytopenia
Budoprutug · 1 upcoming · 1 completed
Phase 1b/2a Data
Q4 2026
IgA Nephropathy
CLYM116 · 2 upcoming · 1 completed
Phase 2 Data: InterimNAVIGATE-2
H1 2027
Phase 3 Study InitiationPivotal
2027
Autoimmune disease· SC formulation
Budoprutug · 1 upcoming
Study Initiation
2027
Primary Membranous Nephropathy
Budoprutug · 1 upcoming · 3 completed
Phase 2 DataPrisMN
2027
Systemic lupus erythematosus
Budoprutug · 1 completed
Phase 1b Data: Interim
Reported Nov 5, 2026
Healthy volunteers
CLYM116 · 1 completed
Phase 1 Data: Topline
Reported Sep 3, 2026
Healthy volunteers
Budoprutug · 1 completed
Phase 1 Data: Interim
Reported May 5, 2026

Dates, trials and completed outcomes are open to everyone. What each upcoming milestone hinges on is part of a subscription.

Quick answers

Is the Climb Bio (CLYM) investment thesis intact?
Yes. Readouts currently rates the Climb Bio Thesis Intact. PrisMN shows antibody reductions; higher-dose ITP and lupus results remain next.
What is the next catalyst for Climb Bio (CLYM)?
The next dated event is Phase 1b/2a results for Budoprutug, expected Q4 2026, as stated by the company. Also ahead: Phase 2 interim results (NAVIGATE-2) for CLYM116, expected H1 2027.
How long will Climb Bio's cash last?
Climb Bio has said its cash will fund operations into the second half of 2028 (guidance as of November 5, 2026). It reported $228 million in cash as of September 30, 2026.

Other companies we cover in these diseases

Immune thrombocytopenia
Agios Pharmaceuticals (AGIO)
Primary Membranous Nephropathy
Travere Therapeutics (TVTX)

Disease areas: Kidney diseases, Blood disorders, Autoimmune and inflammatory diseases
Catalyst calendar · Upcoming FDA decisions · Thesis changes

Competitive landscape

9 peers tracked

For informational purposes only—not investment advice. Always conduct your own research before making investment decisions.

Financial snapshot

Dates and calculation details

Cash: Market-data provider estimate; measurement period unavailable.

Debt: Market-data provider estimate; a complete comparable filing balance is unavailable.

Quarterly burn: Estimated from trailing free cash flow; measurement period unavailable.

Net cash and estimated runway require verified matching measurement periods. Missing debt components are not assumed to be zero.

Runway: No underlying guidance available.